PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Astellas, Veneno Technologies enter research agreement

Japanese-based companies Astellas and Veneno Technologies announced this week that they have entered a joint research agreement to develop functional peptides (DRPs) therapeutics.

Under the terms of the agreement, Astellas will leverage Veneno’s proprietary next-generation peptide discovery technology, the PERISS method (intra-periplasm secretion and selection) to target DRPs for G protein-coupled receptors (GPCRs). 

The PERISS method involves extracting the periplasmic fraction from bacterial cell walls, a space that regulates protein secretion, folding, and degradation. The protein is then released using a mild detergent, and can then be purified and characterized for use in drug development. GPCRs are also known to play a crucial role in cellular communication by receiving neurotransmitters and hormones and regulating the cell’s internal and external environment. 

DRPs refer to peptides that possess a distinct molecular structure with three or more disulfide bonds within the molecule, making them highly resistant to heat, pH changes, and degrading enzymes in comparison to other linear peptides. Because they can act as natural modulators with high potency and selectivity, DRPs have become an attractive novel drug discovery target. 

Veneno is a young company, first established in 2020 and backed by $200M raised during its first funding round. Its president and CEO, Kazunori Yoshikawa, lead AQUA Therapeutics, a fibrotic disease drug development biotech before joining Veneno.

As for Astellas, the biotech has had a busy few weeks, announcing earlier this month that its metastatic urothelial cancer drug had received accelerated approval from the FDA. 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026